Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Deficit)

v3.20.4
Stockholders' Equity (Deficit)
6 Months Ended
Dec. 31, 2020
Equity [Abstract]  
Stockholders' Equity (Deficit)

NOTE 6 - STOCKHOLDERS’ EQUITY (DEFICIT)

 

At-The-Market (“ATM”) Offering

 

2020 ATM Offering

 

On December 21, 2020 the Company entered into a Sales Agreement (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“HCW”) to sell shares of its common stock, par value $0.001 (the “Common Stock”) from time to time, through an “at the market offering” program (the “ATM Offering”) under which HCW will act as sales agent.

 

The Company has agreed to pay HCW a commission in an amount equal to 3.0% of the gross sales proceeds of the shares sold through it as sales agent under the Sales Agreement. In addition, the Company has agreed to reimburse HCW for certain expenses it incurs in the performance of its obligations up to a maximum of $50,000, and $2,500 per quarter thereafter, under the Sales Agreement. The Company has also agreed pursuant to the Sales Agreement to indemnify and provide contribution to HCW against certain liabilities, including liabilities under the Securities Act.

 

In December 2020, the Company sold an aggregate of 226,737 shares of common stock at an average price of $15.40 per share for gross proceeds of approximately $3.5 million in the ATM Offering, prior to deducting commissions and other offering related expenses. The offer and sale of the Shares were made pursuant to the Company’s effective “shelf” registration statement on Form S-3 filed with the Securities and Exchange Commission (the “SEC”) on October 16, 2020, and declared effective by the SEC on October 26, 2020, and a prospectus supplement related to the ATM Offering, dated December 21, 2020.

 

Public Offering

 

2020 Public Offering and NASDAQ Capital Market Uplisting

 

On August 18, 2020, the Company closed an underwritten public offering of its common stock at a public offering price of $4.00 per share for gross proceeds of approximately $12.4 million, which included the full exercise of the underwriters’ over-allotment option to purchase additional shares, prior to deducting underwriting discounts and commissions and offering expenses. A total of 3,099,250 shares of common stock were issued by the Company in the offering, including the full exercise of the over-allotment option. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-231766), which was declared effective by the United States Securities and Exchange Commission on August 12, 2020.

 

Concurrent with the announcement of the public offering, on August 14, 2020, the Company’s common stock commenced trading on The NASDAQ Capital Market under the symbol “FLUX.” Prior to the listing on The NASDAQ Capital Market, the Company’s common stock was quoted on the OTCQB.

 

Private Placements

 

2020 Private Placement

 

On April 22, 2020, the Company sold and issued an aggregate of 66,250 shares of common stock, at $4.00 per share, for an aggregate purchase price of $265,000 in cash to two (2) accredited investors (the “2020 Private Placement”). On June 30, 2020, the Company completed an initial closing of the 2020 Private Placement offering of up to 2,000,000 shares of common stock, pursuant to which the Company sold an aggregate of 275,000 shares of common stock at $4.00 per share, for an aggregate purchase price of $1,100,000 to six (6) accredited investors. The $1,100,000 aggregate purchase price for such shares was paid in cash. Esenjay and Mr. Dutt, the Company’s president and chief executive officer, participated in the initial closing in the amount of $300,000 and $50,000, respectively. On July 24, 2020, the Company sold and issued an aggregate of 800,000 shares of common stock, at $4.00 per share, for an aggregate purchase price of $3,200,000 in cash to accredited investors, including Mr. Cosentino, one of our directors, who participated in the offering in the amount of $250,000.

 

The shares offered and sold in the 2020 Private Placement offering described above were not initially registered under the Securities Act of 1933, as amended (“Securities Act”), and could not have been offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act. As of the issuance date, the shares were offered and sold to the accredited investors in reliance upon exemptions from registration pursuant to Rule 506(b) of Regulation D promulgated under Section 4(a)(2) under the Securities Act. However, pursuant to a Registration on Form S-3 with SEC, which became effective on October 26, 2020, such shares were registered.

 

Debt Conversion

 

LOC Conversion

 

On June 30, 2020, there was a partial conversion of the debt underlying the secured promissory notes issued to lenders under the LOC at a conversion price of $4.00 per share (the “Conversion”). At the option of the lenders, on June 30, 2020, an aggregate of approximately $7,383,000 in principal and accrued interest outstanding under the LOC was converted into 1,845,830 shares of common stock, which consisted of (a) partial conversion of Principal plus interest under the Esenjay LOC Note in the amount of $4,400,000 into 1,100,000 shares of common stock at $4.00 per share, and (b) conversion of approximately $2,983,000 of the secured promissory notes issued in connection with the LOC, principal plus accrued interest, by other lenders, including certain assignees of the Esenjay LOC Note, into 745,830 shares of common stock.

 

On November 6, 2020, there was a partial conversion of the debt underlying the secured promissory notes issued to lenders under the LOC at a conversion price of $4.00 per share (the “November 2020 Conversion”). At the option of the lenders, on November 6, 2020, an aggregate of approximately $2,161,000 in principal and accrued interest outstanding under the LOC was converted into 540,347 shares of common stock.

 

Esenjay Note Conversion

 

On June 30, 2020, two (2) accredited individuals, who became note holders to the Esenjay Note pursuant to the assignment of such notes by Esenjay to the note holders, converted $500,000 in principal into 125,000 shares of common stock at $4.00 per share.

 

On July 22, 2020, one accredited individual, who became note holder to the Esenjay Note pursuant to the assignment of such note by Esenjay to the note holder, converted $400,000 in principal into 100,000 shares of common stock at $4.00 per share.

 

Warrant Activity

 

On July 3, 2019, the Company issued a three-year warrant to Cleveland Capital, L.P.(“Cleveland Warrant”) to purchase our common stock in a number equal to one-half percent (0.5%) of the number of shares of common stock outstanding after giving effect to the total number of shares of common stock sold in a public offering at an exercise price equal to the per share public offering price. On September 1, 2019, the Cleveland Warrant was amended and restated to change the warrant coverage from 0.5% to 1% of the number of shares of common stock outstanding after giving effect to the total number of shares of common stock sold in the next private or public offering (“Offering”) at an exercise price equal the per share price of common stock sold in the Offering. The closing of a private offering constituting the Offering occurred on July 24, 2020. Upon such closing, the number and the exercise price of the Cleveland Warrant became determinable, and represented as a right to purchase up to 83,205 shares of common stock at $4.00 per share and had a fair value of approximately $174,000. As of December 31, 2020, all 83,205 warrants remain outstanding and exercisable.

 

On August 18, 2020 and in conjunction with the Company’s public offering, the Company issued five-year warrants to the underwriters to purchase up to 185,955 shares of the Company’s common stock at an exercise price of $4.80 per share and had a fair value of approximately $513,000. The underwriters’ warrants are exercisable on or after February 8, 2021.

 

Warrant detail for the six months ended December 31, 2020 is reflected below:

 

    Number of Warrants     Weighted Average Exercise Price Per Warrant     Remaining Contract Term (# years)  
Warrants outstanding and exercisable at June 30, 2020     83,205     $ 4.00       2.01  
Warrants issued     185,955     $ 4.80       5.00  
Warrants forfeited     -     $ -       -  
Warrants outstanding at December 31, 2020     269,160     $ 4.55       3.66  
Warrants exercisable at December 31, 2020     83,205     $ 4.00       1.50  

 

Warrant detail for the six months ended December 31, 2019 is reflected below:

 

    Number of Warrants     Weighted Average Exercise Price Per Warrant     Remaining Contract Term (# years)  
Warrants outstanding and exercisable at June 30, 2019     8,333     $ 20.00       0.25  
Warrants issued     -     $ -       -  
Warrants forfeited     (8,333 )   $ 20.00       -  
Warrants outstanding and exercisable at December 31, 2019     -     $ -       -  

 

Stock-based Compensation

 

Stock Options

 

On November 26, 2014, the board of directors approved the 2014 Equity Incentive Plan (the “2014 Plan”), which was approved by the Company’s stockholders on February 17, 2015. The 2014 Plan offers selected employees, directors, and consultants the opportunity to acquire the Company’s common stock and serves to encourage such persons to remain employed by the Company and to attract new employees. The 2014 Plan allows for the award of stock and options, up to 1,000,000 shares of common stock.

 

Activity in stock options during the six months ended December 31, 2020 and related balances outstanding as of that date are reflected below:

 

    Number of Shares     Weighted Average Exercise Price    

Weighted Average Remaining Contract Term

(# years)

 
Outstanding at June 30, 2020     579,584     $ 11.00       7.55  
Granted     -     $ -       -  
Exercised     (10,750 )   $ 4.60       -  
Forfeited and cancelled     (7,463 )   $ 7.31       -  
Outstanding at December 31, 2020     561,371     $ 11.17       6.87  
Exercisable at December 31, 2020     493,224     $ 10.94       6.67  

 

Activity in stock options during the six months ended December 31, 2019 and related balances outstanding as of that date are reflected below:

 

    Number of Shares     Weighted Average Exercise Price    

Weighted Average Remaining

Contract Term

(# years)

 
Outstanding at June 30, 2019     580,171     $ 11.05       8.59  
Granted     -     $ -       -  
Exercised     (4,437 )   $ 4.69       -  
Forfeited and cancelled     (7,093 )   $ 12.32       -  
Outstanding at December 31, 2019     568,641     $ 11.08       8.07  
Exercisable at December 31, 2019     377,428     $ 10.47       7.71  

 

Restricted Stock Units

 

On November 5, 2020, the Company’s Board of Directors approved an amendment to the Company’s 2014 Equity Incentive Plan, as amended (the “2014 Plan”), to include the right to grant Restricted Stock Units (“RSUs”) under the 2014 Plan. Subject to vesting requirements set forth in the RSU Award Agreement, one share of common stock is issuable for one vested RSU. In addition, on November 5, 2020, the Board of Directors established and approved an equity pool of 48,000 shares under the 2014 Plan for the issuance of RSUs to its key employees, the grant of 43,525 RSUs for one-time retention awards to its executive officers, and the grant of 67,785 RSUs under the 2014 Plan to certain employees of the Company, which consisted of; (a) 27,114 time-based RSUs, and (b) 40,671 performance-based RSUs. The RSUs are subject to vesting requirements.

 

Activity in RSUs during the six months ended December 31, 2020 and related balances outstanding as of that date are reflected below:

 

    Number of Shares     Weighted Average Grant date Fair Value    

Weighted Average Remaining Contract Term

(# years)

 
Outstanding at June 30, 2020     -     $ -       -  
Granted     134,865     $ 8.88       -  
Forfeited and cancelled     (4,228 )   $ 8.88       -  
Outstanding at December 31, 2020     130,637     $ 8.88       3.15  

 

There were no RSUs granted or outstanding during the six months ended December 31, 2019.

 

Stock-based compensation

 

Stock-based compensation expense recognized in the condensed consolidated statements of operations for the three and six months ended December 31, 2020 and 2019, includes compensation expense for stock-based options and awards granted based on the grant date fair value. For options and awards granted, expenses are amortized under the straight-line method over the expected vesting period. Stock-based compensation expense recognized in the condensed consolidated statements of operations has been reduced for estimated forfeitures of options and awards that are subject to vesting. Forfeitures are estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

 

At December 31, 2020, the aggregate intrinsic value of exercisable options was approximately $3,325,000.

 

The following table summarizes stock-based compensation expense for employee and non-employee option grants and RSUs:

 

    Three Months Ended
December 31,
    Six Months Ended
December 31,
 
    2020     2019     2020     2019  
Research and development   $ 45,000     $ 54,000     $ 98,000     $ 108,000  
Selling and administrative     152,000       395,000       324,000       792,000  
Total stock-based compensation expense   $ 197,000     $ 449,000     $ 422,000     $ 900,000  

 

The Company uses the Black-Scholes valuation model to calculate the fair value of stock options. The fair value of stock options was measured at the grant date using the assumptions (annualized percentages) in the table below:

 

    Six Months Ended
December 31,
 
    2020     2019  
Expected volatility     0 %     111.4% -112.2 %
Risk free interest rate     0 %     2.43% - 2.45 %
Forfeiture rate     20 %     20 %
Dividend yield     0 %     0 %
Expected term (years)     0       5.61  

 

At December 31, 2020, the unamortized stock-based compensation expense relating to outstanding stock options and RSUs was approximately $589,000 and $737,000, respectively, and these amounts are which is expected to be expensed over the weighted-average remaining recognition period of 1.19 years and 3.15 years, respectively.